Margherita Grasso, Annamaria Fidilio, Francesca L'Episcopo, Marilena Recupero, Concetta Barone, Maria Giulia Bacalini, Cristina Benatti, Maria Concetta Giambirtone, Giuseppe Caruso, Donatella Greco, Santo Di Nuovo, Corrado Romano, Raffaele Ferri, Serafino Buono, A Claudio Cuello, Johanna M C Blom, Fabio Tascedda, Pier Vincenzo Piazza, Rafael De La Torre, Filippo Caraci
Almost all individuals with Down's syndrome (DS) show the characteristic neuropathological features of Alzheimer's disease (AD) by the age of 40, yet not every individual with DS experiences symptoms of AD later in life. Similar to neurotypical developing subjects, AD in people with DS lasts for a long preclinical phase in which biomarkers follow a predictable order of changes. Hence, a prolonged asymptomatic period precedes the onset of dementia, underscoring the importance of identifying new biomarkers for the early detection and monitoring of cognitive decline in individuals with DS...
2024: Frontiers in Pharmacology